SLIDE 38 MMID 2018/2019 :: IHTM :: 6th February 2019
DengvaxiaⓇ
Sanofi Pasteur CYD-TDV Is a live attenuated tetravalent vaccine including the E-protein (envelope) of each of the 4 serotypes. Trials presented
efficacies
- varying efficacies across
serotypes
- consistent results across
the globe Note: efficacy to symptomatic infection.
Asia (trial phase 3) Indonesia, Malaysia, Philippines, Thailand, Vietnam Estimated efficacies DENV1 50% ∊ (25, 67) DENV2 35% ∊ (-9, 61) DENV3 78% ∊ (53,91) DENV4 75% ∊ (54,87) Latin America (trial phase 3) Brazil, Colombia, Honduras, Mexico, Puerto Rico Estimated efficacies DENV1 50% ∊ (29,65) DENV2 42% ∊ (14,61) DENV3 74% ∊ (61,82) DENV4 77% ∊ (60,88) Aggregated efficacy (across serotypes) 74% ∊ (53, 86) in seropositive individuals 35% ∊ (-27, 68) in seronegative individuals